The President of the United Steaks.
Never said when an attack on Syria would take place. Could be very soon or not so soon at all! In any event, the United States, under my Administration, has done a great job of ridding the region of ISIS. Where is our “Thank you America?”
— Donald J. Trump (@realDonaldTrump) April 12, 2018
In other news, futures are +120 — but copper is off by 2.2%. Gold is also down 0.8%, and cryptos are thru the fucking roof.
BTC +13%
ETH +12%
IOT +18%
Perhaps the cryptos are now being recognized as safe havens in lieu of a Syrian attack?
In spite of weakness in commodities, today should be a bullish day.
Here are some other morning headlines.
Gapping up
In reaction to strong earnings/guidance/SSS:
- QNST +11.9%, (also says Kerrisdale claims in negative report are inaccurate), OZRK +3.3%, MDR +3.3%, ZUMZ +3%, (Zumiez reports March comps of +12.6 %vs +1.1% year ago and +9.2% last month), CBSH +3%, RAD +3%, DAL +2%, BLK +1.5%, BKE +1.1%, CBI +0.5%, COST +0.5%, LB +0.5%
Other news:
- CYRN +23.6% (discloses that it has signed a material contract with one of the world’s largest technology companies)
- BLCM +22.6% (FDA has lifted the clinical hold on studies of BPX-501 in the U.S. )
- RETA +11.6% (provides update on the Phase 2 portion of the CARDINAL study of bardoxolone methyl in patients with Alport Syndrome; treatment produced significant increase in kidney function maintained through week 36)
- ALRN +5% (continued strength — company confirmed after the close the publication of nonclinical results in Science Translational Medicine demonstrating the anti-cancer potential of ALRN-6924 in models of Acute Myeloid Leukemia)
- OSTK +4.3% (stronger with Bitcoin +12%)
- ABUS +2.8% (Arbutus Biopharma and Roivant Sciences entered into an agreement to launch Genevant Sciences; Roivant will contribute $37.5 million in transaction-related seed capital)
- CLDR +2.4% (Director disclosed the purchase of 25k shares)
- FEYE +1.1% (continued strength)
- GSK +1.1% (signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics)
Analyst comments:
- FTI +4.6% (upgraded to Buy from Neutral at Goldman)
- INCY +2.3% (upgraded to Buy from Neutral at UBS)
- MYL +1.1% (upgraded to Outperform from Mkt Perform at Leerink Partners)




